FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979889594> ?p ?o ?g. }

• W2979889594 endingPage "303" @default.
• W2979889594 startingPage "303" @default.
• W2979889594 abstract "Abstract Abstract 303 Background: Primary mediastinal large B-cell lymphoma (PMBCL) was distinguished from DLBCL in the REAL/WHO classification by virtue of distinct clinical and pathologic features. In DLBCL, R-CHOP has demonstrated a clear benefit over CHOP chemotherapy in randomized trials, some of which have included a small subset of PMBCL pts (pts). However, large studies evaluating R-CHOP in PMBCL are lacking. Further, the role of consolidative radiotherapy (RT) to the mediastinum remains unclear particularly with the more frequent use of FDG-PET. At the BCCA, from 2001–2005, R-CHOP with consolidative RT was recommended in all pts with PMBCL. After 2005, FDG-PET scan was used to guide RT usage following 6 cycles of R-CHOP. We evaluated: 1) the outcome of pts with PMBCL in R-CHOP vsCHOP treated pts; 2) prognostic factors in R-CHOP treated pts; 3) the impact of the introduction of PET based approach to guide RT compared to the use routine RT. Methods: Using the BC Cancer Agency Centre for Lymphoid Cancer database, we identified all pts with PMBCL by the REAL/WHO classification treated with R-CHOP in addition to an earlier group treated with CHOP chemotherapy. For R-CHOP treated pts, from 2001–2005, consolidative RT to the mediastinumwas routinely administered following R-CHOP (‘RT’ era). Since 2005, a PET was planned at the end of chemotherapy to guide RT (‘PET’ era). If the PET was negative, pts were observed and if the PET was positive, consolidative RT was given, if feasible. Results: In total, 176 pts were identified: 96 received R-CHOP; 80 received CHOP. Baseline clinical features were similar between the treatment groups. Compared to those treated with CHOP, R-CHOP pts had an improved time to progression (TTP) (5 y 78% vs 65%, p=0.018) and overall survival (OS) (5 y 88% vs 70%, p=0.015). Further, refractory disease (progressive disease (PD) on chemotherapy or relapse < 3 months after treatment completion) was more frequent in CHOP treated pts (16% vs 5%, p=0.016). There was no difference in the risk of central nervous system (CNS) relapse (3.2% vs2.1%, p=0.823). For the R-CHOP treated pts, 46 were treated in the ‘RT era’; 80% received consolidative RT; 50 were treated in the ‘PET era’; 38% received RT. In the RT era, there was a greater proportion of pts with extranodal sites > 1 (p=0.007) and the presence of a pleural/pericardial effusion (p=0.009). In an era to era outcome comparison, there was no difference in the 5 y TTP (RT era 76% vs PET era 83%, p=0.626) or 5 y OS (82% vs 89%, p=0.773). In univariate analysis, the presence of B symptoms was associated with an inferior TTP (5 y 67% vs 90%, p=0.014) and OS (5 y 83% vs 94%, p=0.047). An effusion at diagnosis was associated with an inferior TTP (p=0.017) but not OS (p=0.277). Using recursive partitioning, age > 38 y was identified as the optimal cut-off and was associated with an inferior OS (p=0.003) and there was a trend to a worse TTP (p=0.096). The aaIPI was not predictive of TTP (p=0.357) or OS (p=0.386). In multivariate analysis (including variables with p value<.1 and treatment era), B symptoms (HR 4.3 p=0.011), an effusion (HR 2.97, p=0.025) and age > 38 y (HR 2.98, p=0.025) were associated with an inferior TTP. For OS, age > 38 y (HR 6.7, p=0.003) and B symptoms (HR 4.5, p=0.023) were associated with an inferior outcome. Treatment era (RT vsPET) did not affect TTP or OS in MVA. In total, 59 pts treated with R-CHOP had a PET scan at the end of treatment, 50 in the PET era and 9 pts in the ‘RT era’ by self-pay: 35 (59%) were PET-negative (neg) (2 received RT) and 24(41%) were PET-positive (pos) (23 received RT). With a median follow-up of 5.4 y, there was no difference in the TTP (5 y 78% vs 83%, p=0.735) or OS (5 y 88.5% vs 95%, 0.271) for PET-neg and PET-pos cases, respectively. In total, there were 6 relapses in PET-neg cases: 2 CNS and 4 mediastinal. There were 4 relapses in the PET pos cases (PD in the mediastinum at PET scan n=1; within in RT field n=1; within and outside RT field n=1; outside RT field n=1). Conclusion: We confirm the superior outcome using R-CHOP compared to CHOP chemotherapy in PMBCL, however, rituximab does not appear to impact the rare risk of CNS relapse. The introduction of a PET-guided RT approach in R-CHOP treated PMBCL pts has maintained excellent outcomes in the majority of pts while reducing the use of RT. The presence of B symptoms at diagnosis was associated with an increased risk of relapse and may reflect more aggressive underlying disease biology. Disclosures: Savage: Roche: Research Funding. Klasa:F Hoffmann-La Roche (Roche Canada): Consultancy, Research Funding. Villa:F Hoffmann-La Roche (Roche Canada): Consultancy, Research Funding. Slack:F Hoffmann-La Roche (Roche Canada): Consultancy, Research Funding. Gascoyne:F Hoffmann-La Roche (Roche Canada): Consultancy, Research Funding. Connors:Roche: Research Funding. Sehn:F. Hoffmann-La Roche (Roche Canada): Research Funding." @default.
• W2979889594 created "2019-10-18" @default.
• W2979889594 creator A5017873196 @default.
• W2979889594 creator A5022658681 @default.
• W2979889594 creator A5023202154 @default.
• W2979889594 creator A5026641386 @default.
• W2979889594 creator A5031758990 @default.
• W2979889594 creator A5037428122 @default.
• W2979889594 creator A5042630106 @default.
• W2979889594 creator A5045731423 @default.
• W2979889594 creator A5048030695 @default.
• W2979889594 creator A5059082232 @default.
• W2979889594 creator A5061168739 @default.
• W2979889594 date "2012-11-16" @default.
• W2979889594 modified "2023-09-30" @default.
• W2979889594 title "The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era" @default.
• W2979889594 doi "https://doi.org/10.1182/blood.v120.21.303.303" @default.
• W2979889594 hasPublicationYear "2012" @default.
• W2979889594 type Work @default.
• W2979889594 sameAs 2979889594 @default.
• W2979889594 citedByCount "30" @default.
• W2979889594 countsByYear W29798895942014 @default.
• W2979889594 countsByYear W29798895942015 @default.
• W2979889594 countsByYear W29798895942016 @default.
• W2979889594 countsByYear W29798895942017 @default.
• W2979889594 countsByYear W29798895942018 @default.
• W2979889594 countsByYear W29798895942019 @default.
• W2979889594 countsByYear W29798895942020 @default.
• W2979889594 countsByYear W29798895942021 @default.
• W2979889594 countsByYear W29798895942022 @default.
• W2979889594 crossrefType "journal-article" @default.
• W2979889594 hasAuthorship W2979889594A5017873196 @default.
• W2979889594 hasAuthorship W2979889594A5022658681 @default.
• W2979889594 hasAuthorship W2979889594A5023202154 @default.
• W2979889594 hasAuthorship W2979889594A5026641386 @default.
• W2979889594 hasAuthorship W2979889594A5031758990 @default.
• W2979889594 hasAuthorship W2979889594A5037428122 @default.
• W2979889594 hasAuthorship W2979889594A5042630106 @default.
• W2979889594 hasAuthorship W2979889594A5045731423 @default.
• W2979889594 hasAuthorship W2979889594A5048030695 @default.
• W2979889594 hasAuthorship W2979889594A5059082232 @default.
• W2979889594 hasAuthorship W2979889594A5061168739 @default.
• W2979889594 hasConcept C126322002 @default.
• W2979889594 hasConcept C126838900 @default.
• W2979889594 hasConcept C143998085 @default.
• W2979889594 hasConcept C2776694085 @default.
• W2979889594 hasConcept C2779126056 @default.
• W2979889594 hasConcept C2779338263 @default.
• W2979889594 hasConcept C2779725641 @default.
• W2979889594 hasConcept C71924100 @default.
• W2979889594 hasConceptScore W2979889594C126322002 @default.
• W2979889594 hasConceptScore W2979889594C126838900 @default.
• W2979889594 hasConceptScore W2979889594C143998085 @default.
• W2979889594 hasConceptScore W2979889594C2776694085 @default.
• W2979889594 hasConceptScore W2979889594C2779126056 @default.
• W2979889594 hasConceptScore W2979889594C2779338263 @default.
• W2979889594 hasConceptScore W2979889594C2779725641 @default.
• W2979889594 hasConceptScore W2979889594C71924100 @default.
• W2979889594 hasIssue "21" @default.
• W2979889594 hasLocation W29798895941 @default.
• W2979889594 hasOpenAccess W2979889594 @default.
• W2979889594 hasPrimaryLocation W29798895941 @default.
• W2979889594 hasRelatedWork W2045177263 @default.
• W2979889594 hasRelatedWork W2049214470 @default.
• W2979889594 hasRelatedWork W2050334765 @default.
• W2979889594 hasRelatedWork W2110443444 @default.
• W2979889594 hasRelatedWork W2170671836 @default.
• W2979889594 hasRelatedWork W2341761393 @default.
• W2979889594 hasRelatedWork W2374533761 @default.
• W2979889594 hasRelatedWork W3031860663 @default.
• W2979889594 hasRelatedWork W3037744540 @default.
• W2979889594 hasRelatedWork W4242755150 @default.
• W2979889594 hasVolume "120" @default.
• W2979889594 isParatext "false" @default.
• W2979889594 isRetracted "false" @default.
• W2979889594 magId "2979889594" @default.
• W2979889594 workType "article" @default.